The company strategy that we maintained from inception to our recent reverse split (July, 2008) had been one of research only. We focused all our energies, talent, and resources to the incubation and growth of new ideas in the realm of genetically engineered disease detection and vaccination. We feel that with recent announcements the company is positioned to move from a developmental stage to a product oriented stage
RECENT DEVELOPMENTS
Our recent developments include the progress we are making in regards to
our Johne's Disease validation trials scheduled to begin in collaboration with
the Universidad National Autonoma de
The recent signing of our agreement with STC.UNM (the technology
development arm of The
GeneThera is working with The Goldsmith Group LLC for continued
improvement of the company image and support for its shareholders. The
Goldsmith Group is a private PR and Marketing firm whose members have
extensive experience in the managing and marketing of both private and
publicly traded firms throughout the US and
Comments from our Chairman
GeneThera Chairman and CEO, DR.
Dr. Milici went on to state ... "We are now ready to start the validation
trials for our Johne's Disease test in
With the change coming in the Presidential administration, GeneThera expects many of the previous testing requirements that had been considered by our government to be re-instated. This will only serve to better the position of GeneThera and its shareholders, as we have several testing methods to detect such pathogens as Mad Cow Disease, CWD, Johne's Disease, E.Coli 0157:h7, and others. These are all pathogens that have a serious affect on our food supply from both a safety and an economic standpoint. If/when testing for these pathogens becomes mandatory; GeneThera will already be in a position to capitalize on them.
In conclusion, we at GeneThera want to once again thank our loyal shareholders for their continued support. We encourage you to contact us for more details on our plans and expectations for the future.
About Johne's Disease
Johne's (pronounced "Yo-nees") disease is a contagious bacterial disease of the intestinal tract. A German veterinarian first described the disease in a dairy cow in 1895; his name is used as the common name for the disease. The disease is also called paratuberculosis. Visit the history page for detailed information.
Johne's disease occurs in a wide variety of animals, but most often in ruminants. Ruminants are hoofed mammals that chew their cud and have a four-chambered stomach. Some of the more common ruminants are: cattle, sheep, goats, deer, antelope, and bison. Johne's disease has been reported in all of these animals but is most commonly seen in dairy cattle. The result most commonly reported from infected cattle is a serious decline in herd milk production. The animal develops uncontrolled diarrhea and slowly wastes away to a point of death.
The U.S. rate of dairy herd infection is similar to that reported in other
countries using similar tests:
About E.Coli 057.h7
There are a variety of Escherichia coli bacteria present in nature. They
are usually found in the intestines of healthy humans and healthy animals.
Even though these bacteria offer beneficial properties, there are those
variations, or strains that are pathogenic (have the ability to cause
disease). Escherichia coli 0157:H7 is one particular strain that is "... an
emerging cause of food borne illness ..." Symptoms such as bloody diarrhea and
abdominal cramps may be observed or no such symptoms may appear. The elderly
and children under five years old are highly susceptible to Hemolytic Uremic
Syndrome, a disease in which red blood cells are destroyed and kidneys fail.
According to the CDC " ... there may be about 70,000 infections with E. coli
O157 each year in
ABOUT GENETHERA, INC.
GeneThera, Inc., is a molecular biotechnology company located in
This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
Dr.
Goldsmith Group 303-838-4370
JR Dopkin & Associates 516-884-3200
SOURCE GeneThera, Inc.